EL.PA EssilorLuxottica S. A.

Healthcare Health Care Equipment & Supplies Euronext Paris
193.80 EUR
Close of Nov 8, 2026
138.30 316.32
Market cap
EUR 88.8B
P/E
36.2x
P/B
2.27x
ROE
16.0%
Dividend yield
0.62%
Fundamental score
2.8/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is EL.PA undervalued?

Graham number
Price193.80
Graham value101.48
Premium91.0%

EL.PA trades 91.0% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

EssilorLuxottica S. A. fundamental analysis

9 of 11 checks passed

ROE 1/2

ROE in an average range (4.04%) suggests satisfactory profitability and decent utilization of shareholders' equity.

ROA 1/2

The stock's ROA (6.24%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

PBV 1/2

The stock's PBV ratio (2.09x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

DER 2/2

The stock has a minimal amount of debt (31%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

Revenue Growth 1/2

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

Net Profit Growth 1/2

This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity.

Assets Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Graham Number 0/1

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

Dividend Growth 1/2

The company's dividend growth has exhibited a remarkable upward trend over the past three years, consistently delivering higher payouts to shareholders.

Dividend 2/2

Shareholders can rely on the company's remarkable dividend history, consistently paying dividends for the past five years, demonstrating a steadfast dedication to rewarding investors.

Buffet Intrinsic Value 1/1

Warren Buffett's formula suggests that the company's stock is undervalued (5.737), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

EssilorLuxottica S. A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About EssilorLuxottica S. A.

EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, sunglasses, and instruments and equipment in North America, the Middle East, Africa, Europe, Latin America, and the Asia-Pacific. It offers lens, eyewear, contact lenses, reading glasses under Essilor, Varilux, Crizal, Eyezen, Stellest, Xperio, Transitions, Ray-Ban, Oakley, Barberini, KODAK Lens, Nikon, Shamir Optical, eyexpert, iWear, Humanware, Optifog, Persol, Oliver Peoples…

Full company profile